Navigation Links
European Prices of 170 Best-Selling Drugs Averaged 40 Percent Less Than U.S. Prices in 2008
Date:7/7/2009

WALTHAM, Mass., July 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that European prices of 170 best-selling drugs averaged 40 percent less than U.S. prices in 2008. Within Europe prices varied substantially, from an average of 55 percent of U.S. prices in Italy to 70 percent of U.S. prices in Germany. European prices for biologics averaged 86 percent of U.S. prices.

Many of the drugs that have the largest percentage price differentials between the United States and other markets are older drugs such as Eli Lilly's Prozac, Sanofi-Aventis' Ambien and Novartis' Tegretol that have lost patent protection in some markets. Manufacturers of branded medicines in Europe typically cut the prices of these drugs when the products lose patent protection, whereas companies in the United States usually maintain brand prices following patent expiration.

"The current economic downturn will focus increasing attention on the cost of prescription drugs, and many payers will look to compare the prices they pay with prices in other markets. The United States is widely assumed to be by far the most expensive pharmaceutical market, but pharmaceutical companies and payers need to be aware of the enormous price variations by therapeutic area and drug type from one country to another," stated Neil Grubert, M.A., Director of Pricing and Reimbursement Research at Decision Resources.

About 2009 Chartbook of International Pharmaceutical Prices

The new Spectrum report entitled 2009 Chartbook of International Pharmaceutical Prices examines overall price differentials among seven of the world's largest pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan) and reviews pricing hierarchies in each of these markets. The report also analyzes price variations by therapeutic area, considers the prices of biologics, and assesses the outlook and implications for the pharmaceutical industry.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Gisselle Morales              Elizabeth Marshall
    Decision Resources            Decision Resources, Inc.
    781-296-2691                  781-296-2563
    gmorales@dresources.com       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market
2. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
3. Euro RSCG Life Acquires Medicom Group to Further Strengthen Its Global and European Medical Education Offering
4. Frost & Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon
5. Simbionix Signs Agreement With the European Association for Endoscopic Surgery
6. The European Association for the Study of the Liver renews publishing partnership with Elsevier
7. Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan
8. Prostate screening studies reviewed in European Urology July issue
9. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
10. European researchers look for new ways to fight multi-drug-resistant bacterial infections
11. Verizon Private IP Quadruples Network Capacity for Invacares European Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence ... and the most minimally invasive approaches. , Women who have had multiple vaginal ... risk factors include surgery to the pelvic floor, connective tissue disorders, and obesity. ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... and Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically ... newly approved FDA injectable medication used as a non-surgical alternative for reduction of ...
(Date:2/6/2016)... , ... February 06, 2016 , ... With the ... add warm color grades to their footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. By manipulating each pixel, LUT's can ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran ... it started in 2003. This year, he ran all 26.2 miles with a green ... team the Miami Heat. , This Sunday, while many are watching the Superbowl, Steven ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Obstetrics Partnering 2010-2016: ... profile to their offering. --> ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> Research ...
(Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
(Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
Breaking Medicine Technology: